Incanthera established as a spin-out from the University of Bradford Institute of Cancer Therapeutics (ICT).
Receives first institutional investment alongside assignment of intellectual property and enters into the Pipeline Agreement with ICT.
Receives further institutional investment for the development of a revolutionary new cancer therapy arising from ICT. The Company uses the investment to complete several pre-clinical studies adding significant value to its rapidly increasing data package.
Launches a partnership with global investment group Technomark Life Sciences. The two businesses begin to work together to prepare ICT2588 Incanthera’s revolutionary treatment for solid tumours – for clinical trials.
Acquires Onco-NX, an anticancer drug discovery Company. Begins an advanced preclinical
programme for ICT03-Es5. Granted a patent in the US and Japan for ICT01-2588.
Completes a successful fundraise of £1.3m., acquires a new drug programme through Spear Therapeutics Limited and acquires further technology through the Pipeline Agreement.
Incanthera is granted patents in Great Britain and the US for its programme ICT03-EsS and acquires further technology through the Pipeline Deal.
Incanthera signs first commercial deal for the Company’s lead asset, ICT01-2588.
Incanthera signs extension to the unique pipeline deal with the ICT for a further ten years.
Acquisition of technology for innovative topical application for solar keratosis and melanoma, Sol.
Incanthera announces successful flotation on London’s AQSE Growth Market.
Major progress with Sol achieved - read more